Business Context and Reporting Period
Company: NANOVIRICIDES, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: July 7, 2009
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. The filing text does not provide revenue, profit, cash flow, margins, or existing debt levels.
| Metric | Value |
|---|---|
| Common Stock Sold | 2,100,700 shares |
| Warrants Issued | 1,050,350 warrants |
| Warrant Exercise Price | $1.00 per share |
| Warrant Expiration | 5 years from issuance |
| Total Proceeds | $1,050,350 |
Material Changes
On July 7, 2009, the company consummated subscriptions with certain investors. This transaction resulted in the issuance of 2,100,700 shares of common stock and warrants to purchase an additional 1,050,350 shares. The securities were sold for an aggregate purchase price of $1,050,350.
Guidance, Outlook, and Risks
Regulatory Status: The securities were offered and sold in reliance on exemptions from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D.
Investor Qualifications: Investors represented they are "accredited investors" with access to information regarding the company's operations and financial condition.
Restrictions: The securities are deemed restricted and may not be resold or offered in the United States without registration or an applicable exemption. Certificates bear legends to this effect.
Outlook: The filing text does not provide management commentary, future guidance, or specific risk factors beyond the standard restrictions on resale.
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the current cash position of the company to determine the immediate liquidity benefit of the $1,050,350 raise.
- Review the full Subscription Agreement (Exhibit 10.1) for any covenants or conditions attached to the investment.
- Check subsequent filings for the use of proceeds and any further equity issuances.